<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/latestarticles/journal?journal=bmccomplementalternmed&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Complementary and Alternative Medicine - Latest Articles</title>
        <link>http://www.biomedcentral.com/bmccomplementalternmed/</link>
        <description>The latest research articles published by BMC Complementary and Alternative Medicine</description>
        <dc:date>2009-07-08T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/22" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/21" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/20" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/19" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/18" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/17" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/16" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/15" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/14" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1472-6882/9/13" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/22">
        <title>Dark chocolate or tomato extract for prehypertension: a randomised controlled trial</title>
        <description>Background:
Flavanol-rich chocolate and lycopene-rich tomato extract have attracted interest as potential alternative treatment options for hypertension, a known risk factor for cardiovascular morbidity and mortality. Treatment of prehypertension (SBP 120-139/ DBP 80-89 mmHg) may forestall progression to hypertension. However, there has been only limited research into non-pharmacological treatment options for prehypertension. We investigated the effect of dark chocolate or tomato extract on blood pressure, and their acceptability as an ongoing treatment option in a prehypertensive population.
Methods:
Our trial consisted of two phases: a randomised controlled three-group-parallel trial over 12 weeks (phase 1) followed by a crossover of the two active treatment arms over an additional 12-week period (phase 2). Group 1 received a 50g daily dose of dark chocolate with 70% cocoa containing 750mg polyphenols, group 2 were allocated one tomato extract capsule containing 15mg lycopene per day, and group 3 received one placebo capsule daily over 8 weeks followed by a 4-week washout period. In phase 2 the active treatment groups were crossed over to receive the alternative treatment. Median blood pressure, weight, and abdominal circumference were measured 4-weekly, and other characteristics including physical activity, general health, energy, mood, and acceptability of treatment were assessed by questionnaire at 0, 8 and 20 weeks. We analysed changes over time using a linear mixed model, and one time point differences using Kruskal-Wallis, Fisher&apos;s-Exact, or t-tests.
Results:
Thirty-six prehypertensive healthy adult volunteers completed the 6-month trial. Blood pressure changes over time within groups and between groups were not significant and independent of treatment. Weight and other characteristics did not change significantly during the trial. However, a marked difference in acceptability between the two treatment forms (chocolate or capsule) was revealed (p&lt;0.0001). Half of the participants allocated to the chocolate treatment found it hard to eat 50g of dark chocolate every day and 20% considered it an unacceptable long-term treatment option, whereas all participants found it easy and acceptable to take a capsule each day for blood pressure.
Conclusion:
Our study did not find a blood pressure lowering effect of dark chocolate or tomato extract in a prehypertensive population. Practicability of chocolate as a long-term treatment option may be limited.Trial registration: www.anzctr.org.au  Identifier: ACTRN12609000047291</description>
        <link>http://www.biomedcentral.com/1472-6882/9/22</link>
                <dc:creator>Karin Ried</dc:creator>
                <dc:creator>Oliver Frank</dc:creator>
                <dc:creator>Nigel Stocks</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:22</dc:source>
        <dc:date>2009-07-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-22</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2009-07-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/21">
        <title>Assessment of the medicinal potentials of the methanol extracts of the leaves and stems of Buddleja saligna.</title>
        <description>Background:
Buddleja saligna Willd (Loganiaceae) is a small to medium-sized evergreen tree; trunk short, often gnarled and crooked; crown dense, rounded or domed-shaped; foliage greyish green. The wild olives are traditionally used to lower blood pressures in many parts of the world. In southern Africa, bark and leaf decoctions are used to treat colic, coughs, colds, sore eyes, urinary problems and as purgatives.
Methods:
The antibacterial, antioxidant activities and phenolic contents of the methanol extracts of the leaves and stems of Buddleja saligna were evaluated using in vitro standard methods. Spectrophotometry was the basis for the determinations of total phenol, total flavonoids, flavonols, and proanthocyanidins. Tannins, quercetin and catechin equivalents were used for these parameters. The antioxidant activities of the leaves and stem extracts of Buddleja saligna were determined by ABTS, DPPH, and ferrous reducing antioxidant property (FRAP) methods. Laboratory isolates of 10 bacteria species which included five Gram-positive and five Gram-negative strains were used to assay for antibacterial activity of this plant.
Results:
The antioxidant activities of the leaves as determined by the ABTS and DPPH were similar to that of the stem. The flavonoids and the flavonols contents of the leaves were higher than that of the stem but the total phenols, proanthocyanidins and FRAP activities were higher in the methanol extracts of the stem. The extracts did show activity against both Gram-positive and Gram-negative bacteria. For instance, while the methanol extract of the leaves showed good activities on all the organisms except Serratia marcescens and Pseudomonas aeruginosa at MICs of between 2.5 and 5.0 mg/ml, the extract of the stem only showed activities on Bacillus cereus, Streptococcus pyrogens and Pseudomonas aeruginosa at the same concentration.
Conclusion:
The results from this study indicate that the leaves and stem extracts of Buddleja saligna possess antioxidant properties and could serve as free radical inhibitors or scavenger or, acting possibly as primary antioxidants. Although, the antibacterial properties of Buddleja saligna are not as effective as the standard drugs-Chloramphenicol and Streptomycin, they still possess some activity against bacterial strains used in this study. Buddleja saligna may therefore be a good candidate for functional foods as well as pharmaceutical plant-based products.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/21</link>
                <dc:creator>Adeolu Adedapo</dc:creator>
                <dc:creator>Florence Jimoh</dc:creator>
                <dc:creator>Srinivas Vedic</dc:creator>
                <dc:creator>Patrick Masika</dc:creator>
                <dc:creator>Anthony Afolayan</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:21</dc:source>
        <dc:date>2009-07-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-21</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2009-07-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/20">
        <title>Anti-tumor effect of Liqi, a traditional Chinese medicine prescription, in tumor bearing mice</title>
        <description>Background:
Liqi, an herbal preparation used in traditional Chinese medicine, has been used to treat cancer in China for centuries. We investigated the anti-tumor effects of liqi and their mechanisms in mice that had been xenografted with tumors.
Methods:
Sarcoma 180 tumor, Lewis lung carcinoma, and SGC-7901 cells were implanted in BALB/c mice, C57BL/6 mice, and BALB/c nude mice, respectively. Liqi was administered to subgroups of these mice. The tumor weight and size were measured. Cell cycle assay and T lymphocyte subsets were determined by flow cytometry. The activity of NK cells and TNF was tested using cytotoxicity assay on YAC-1 cells and L929 cells, respectively, and the activity of IL-2 was tested with an IL-2-dependent CTLL-2 cell proliferation assay. Platelet aggregation was monitored by measuring electric impedance, and the levels of thromboxane A2 (TXA2) and prostacyclin (PGI2) in blood were measured by 125I-TXB2 and 125I-Keto-PGF1alpha radioimmunoassay.
Results:
The results showed that liqi inhibited tumor growth in tumor-implanted mice and arrested the cell proliferation in the G0/G1 phase and reduced the portion of cells in S and G2/M phase for SGC-7901 cells. Liqi increased the activity of NK cells and TNF-alpha, stimulated IL-2 production and activity, and regulated T lymphocyte subpopulations. Liqi inhibited the Lewis lung carcinoma metastasis by inhibiting platelet aggregation and normalizing the balance between TXA2 and PGI2.
Conclusions:
All these findings demonstrated that liqi has an anti-tumor effect in vivo. The mechanism may be related to immune regulation and anticoagulation effects.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/20</link>
                <dc:creator>Deng-Bo Ji</dc:creator>
                <dc:creator>Jia Ye</dc:creator>
                <dc:creator>Yi-Min Jiang</dc:creator>
                <dc:creator>Bo-Wen Qian</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:20</dc:source>
        <dc:date>2009-07-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-20</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2009-07-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/19">
        <title>The potential of complementary and alternative medicine in promoting well-being and critical health literacy: a prospective, observational study of shiatsu</title>
        <description>Background:
The potential contribution of complementary and alternative medicine (CAM) modalities to promote and support critical health literacy has not received substantial attention within either the health promotion or the CAM literature. This paper explores the potential of one CAM modality, shiatsu, in promoting well-being and critical health literacy.
Methods:
Data are drawn from a longitudinal, 6 months observational, pragmatic study of the effects and experience of shiatsu within three European countries (Austria, Spain and the UK). Client postal questionnaires included: advice received, changes made 6 months later, clients &apos;hopes&apos; from having shiatsu and features of the client-practitioner relationship.ResultAt baseline, three-quarters of clients (n = 633) received advice, on exercise, diet, posture, points to work on at home or other ways of self-care. At 6 months follow-up, about four-fifths reported making changes to their lifestyle &apos;as a result of having shiatsu treatment&apos;, including taking more rest and relaxation or exercise, changing their diet, reducing time at work and other changes such as increased body/mind awareness and levels of confidence and resolve. Building on the findings, an explanatory model of possible ways that a CAM therapy could contribute to health promotion is presented to guide future research, both within and beyond CAM.
Conclusion:
Supporting individuals to take control of their self-care requires advice-giving within a supportive treatment context and practitioner relationship, with clients who are open to change and committed to maintaining their health. CAM modalities may have an important role to play in this endeavour.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/19</link>
                <dc:creator>Andrew Long</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:19</dc:source>
        <dc:date>2009-06-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-19</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2009-06-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/18">
        <title>Evaluating complex health interventions: a critical analysis of the &apos;outcomes&apos; concept</title>
        <description>Background:
The extent to which a health care intervention causes or facilitates health-related change is a key question in research. The need to quantify such change has led to the development of an increasing number of change indicators, to measure what have come to be known as &apos;outcomes&apos;. In the context of medical research into the efficacy or effectiveness of an intervention the term &apos;outcomes&apos; has often been interpreted to mean single endpoints with a linear cause and effect link to an external intervention.DiscussionIn this paper we present a critical analysis of the nature and interpretation of the &apos;outcomes&apos; concept and of the assumptions that underpin it. Drawing on our own work and that of others, we analyse the problems that arise when the concept is applied to complex interventions and discuss the use of other models, such as programme theory, as a basis for alternative conceptualisations for indicators of change.Our analysis demonstrates that the interpretation of &apos;outcomes&apos; that may be appropriate for clinical trials of pharmaceutical products, is problematic when used in evaluations of complex interventions in areas such as complementary medicine, palliative care, rehabilitation, and health promotion. The &apos;outcomes&apos; concept may impose inappropriate patterns of thought and meaning. We present alternative models, such as those based on programme theory, which conceptualise health-related change as resulting from the interaction between intervention, process and context over time. In this framework both the intervention and the patient are defined as causal factors, because the result of the treatment is dependent on the resources of the patient - such as the body&apos;s ability to heal itself - and the impact of the patient&apos;s situation.SummaryEvaluations based on a model such as programme theory will encompass a wide range of health-related changes that include aspects of process, such as new meanings and understanding, as well as longer term changes in health, wellbeing and health-related competences and behaviours.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/18</link>
                <dc:creator>Charlotte Paterson</dc:creator>
                <dc:creator>Charlotte Baarts</dc:creator>
                <dc:creator>Laila Launso</dc:creator>
                <dc:creator>Marja Verhoef</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:18</dc:source>
        <dc:date>2009-06-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-18</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2009-06-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/17">
        <title>Animal-based folk remedies sold in public markets in Crato and Juazeiro do Norte, Ceara, Brazil</title>
        <description>Background:
Human communities consistently develop a detailed knowledge of the therapeutical and medicinal properties of the local flora and fauna, and these folk remedies often substitute medicines produced by the pharmaceutical industry. Animals (and their derived products) are essential ingredients in the preparation of many traditional remedies. The present work prepared an inventory of the animals sold in public markets in the cities of Crato and Juazeiro do Norte, Cear&#225; State, Brazil.
Methods:
Information was obtained through the use of semi-structured questionnaires in interviews held with 27 merchants of medicinal animals (18 in the municipality of Juazeiro do Norte [11 men and 7 women] and 9 people in the municipality of Crato [6 men and 3 women]). We calculated the Informant Consensus Factor (ICF) to determine the consensus over which species are effective for particular ailments, as well as the species Use Value (UV) to determine the extent of utilization of each species.
Results:
A total of 31 animal species, distributed among 21 families were identified as being used medicinally. The taxa most represented were: insects (8 species), mammals (7), fish (5), reptiles (5) and birds (4). The animals sold in these markets are used to treat a total of 24 ailments, with rheumatism, asthma, and inflammations having the largest numbers of citations. Three species not previously reported as having medicinal use were encountered: Leporinus steindachneri (utilized for treating cholesterol problems), Gryllus assimilis (utilized in treating urinary infections), and Phrynops tuberosus (used to treat asthma, rheumatism and bruises).
Conclusion:
The composition of the local fauna, the popular culture, and commercial considerations are factors that maintain and drive the market for therapeutic animal products &#8211; and the lack of monitoring and regulation of this commerce is worrisome from a conservationist perspective. A detailed knowledge of the fauna utilized in alternative medicine is fundamental to the conservation and rational use of the Brazilian fauna.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/17</link>
                <dc:creator>Felipe Ferreira</dc:creator>
                <dc:creator>Samuel Brito</dc:creator>
                <dc:creator>Samuel Ribeiro</dc:creator>
                <dc:creator>Antonio Saraiva</dc:creator>
                <dc:creator>Waltecio Almeida</dc:creator>
                <dc:creator>Romulo Alves</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:17</dc:source>
        <dc:date>2009-06-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-17</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2009-06-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/16">
        <title>Bach Flower Remedies for psychological problems and pain: a systematic review</title>
        <description>Background:
Bach Flower Remedies are thought to help balance emotional state and are commonly recommended by practitioners for psychological problems and pain. We assessed whether Bach Flower Remedies (BFRs) are safe and efficacious for these indications by performing a systematic review of the literature.
Methods:
We searched MEDLINE&#174;, Embase, AMED, and the Cochrane Library from inception until June 2008 and performed a hand-search of references from relevant key articles. For efficacy, we included all prospective studies with a control group. For safety, we also included retrospective, observational studies with more than 30 subjects. Two authors abstracted data and determined risk of bias using a recognised rating system of trial quality.
Results:
Four randomised controlled trials (RCTs) and two additional retrospective, observational studies were identified and included in the review. Three RCTs of BFRs for students with examination anxiety, and one RCT of BFRs for children with attention-deficit hyperactivity disorder (ADHD) showed no overall benefit in comparison to placebo. Due to the number and quality of the studies the strength of the evidence is low or very low. We did not find any controlled prospective studies regarding the efficacy of BFRs for pain. Only four of the six studies included for safety explicitly reported adverse events.
Conclusion:
Most of the available evidence regarding the efficacy and safety of BFRs has a high risk of bias. We conclude that, based on the reported adverse events in these six trials, BFRs are probably safe. Few controlled prospective trials of BFRs for psychological problems and pain exist. Our analysis of the four controlled trials of BFRs for examination anxiety and ADHD indicates that there is no evidence of benefit compared with a placebo intervention.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/16</link>
                <dc:creator>Kylie Thaler</dc:creator>
                <dc:creator>Angela Kaminski</dc:creator>
                <dc:creator>Andrea Chapman</dc:creator>
                <dc:creator>Tessa Langley</dc:creator>
                <dc:creator>Gerald Gartlehner</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:16</dc:source>
        <dc:date>2009-05-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-16</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2009-05-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/15">
        <title>Anti-angiogenic effects of pterogynidine alkaloid isolated from Alchornea glandulosa </title>
        <description>Background:
Angiogenesis, a complex multistep process that comprehends proliferation, migration and anastomosis of endothelial cells (EC), has a major role in the development of pathologic conditions such as inflammatory diseases, tumor growth and metastasis. Brazilian flora, the most diverse in the world, is an interesting spot to prospect for new chemical leads, being an important source of new anticancer drugs. Plant-derived alkaloids have traditionally been of interest due to their pronounced physiological activities. We investigated the anti-angiogenic potential of the naturally occurring guanidine alkaloid pterogynidine (Pt) isolated from the Brazilian plant Alchornea glandulosa. The purpose of this study was to examine which features of the angiogenic process could be disturbed by Pt.
Methods:
Human umbilical vein endothelial cells (HUVEC) were incubated with 8 &#956;M Pt and cell viability, proliferation, apoptosis, invasion and capillary-like structures formation were addressed. Nuclear factor &#954;B (NF&#954;B), a transcription factor implicated in these processes, was also evaluated in HUVEC incubated with Pt. Quantifications were expressed as mean &#177; SD of five independent experiments and one-way analysis of variance (ANOVA) followed by the Dunnet test was used.
Results:
A significant decrease in proliferation and invasion capacity and an effective increase in apoptosis as assessed by bromodeoxyuridine (BrdU), double-chamber and terminal transferase dUTP nick end labeling (TUNEL) assay, respectively, have been found. Pt also led to a drastic reduction in the number of capillary-like structures formation when HUVEC were cultured on growth factor reduced-Matrigel (GFR-Matrigel) coated plates. In addition, incubation of HUVEC with Pt resulted in reduced NF&#954;B activity.
Conclusion:
These findings emphasize the potential use of Pt against pathological situations where angiogenesis is stimulated as tumor development.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/15</link>
                <dc:creator>Flavia Lopes</dc:creator>
                <dc:creator>Ana Rocha</dc:creator>
                <dc:creator>Ana Pirraco</dc:creator>
                <dc:creator>Luis Regasini</dc:creator>
                <dc:creator>Dulce Silva</dc:creator>
                <dc:creator>Vanderlan Bolzani</dc:creator>
                <dc:creator>Isabel Azevedo</dc:creator>
                <dc:creator>Iracilda Carlos</dc:creator>
                <dc:creator>Raquel Soares</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:15</dc:source>
        <dc:date>2009-05-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-15</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2009-05-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/14">
        <title>The use of herbal medicines by people with cancer: a qualitative study</title>
        <description>Background:
Between 7% and 48% of cancer patients report taking herbal medicines after diagnosis. Because of the possibility of unwanted side effects or interactions with conventional treatments, people with cancer are generally advised to tell the professionals treating them if they are taking any form of medication, including herbal medicines and supplements. Studies suggest that only about half do so and that the professionals themselves have at best very limited knowledge and feel unable to give informed advice. This study is intended to inform the future development of information resources for cancer patients, survivors and healthcare professionals including tools for use before or during consultation to make it easier for patients to mention, and for healthcare professionals to ask about, use of herbal medications.Methods/designThis is a three-phase study. In phase 1, a systematic review of the literature on self-medication with herbal medicines among UK populations living with cancer will establish the current evidence base on use of herbal medicine, sources of information, characteristics and motivations. This will allow us to better understand what aspects need further investigation and inform the topic guide for a qualitative study (phase 2). Six focus groups of six to eight cancer patients who have used at least one herbal preparation since diagnosis will explore behaviour, beliefs, knowledge, information sources and needs in an informal conversational setting.Informed by the findings of the systematic review and qualitative study, in phase 3 we will construct and pilot a questionnaire for a future large-scale survey to quantify and prioritise people&apos;s beliefs, needs and information preferences.DiscussionDespite known interactions with conventional cancer treatments and contraindications for some herbal remedies with specific cancers, reliable information resources for patients are very limited. Identifying cancer patients&apos; information needs and preferences is the first step in creating a suitable resource for both the public and the professionals advising them.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/14</link>
                <dc:creator>Christine Gratus</dc:creator>
                <dc:creator>Sue Wilson</dc:creator>
                <dc:creator>Sheila Greenfield</dc:creator>
                <dc:creator>Sarah Damery</dc:creator>
                <dc:creator>Sally Warmington</dc:creator>
                <dc:creator>Robert Grieve</dc:creator>
                <dc:creator>Neil Steven</dc:creator>
                <dc:creator>Philip Routledge</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:14</dc:source>
        <dc:date>2009-05-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-14</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2009-05-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1472-6882/9/13">
        <title>Herbal therapy associated with antibiotic therapy: potentiation of the antibiotic activity against methicillin - resistant Staphylococcus aureus by Turnera ulmifolia L.</title>
        <description>Background:
Staphylococcus genus is widely spread in nature being part of the indigenous microbiota of skin and mucosa of animal and birds. Some Staphylococcus species are frequently recognized as etiological agents of many animal and human opportunistic infections This is the first report testing the antibiotic resistance-modifying activity of Turnera ulmifolia against methicillin-resistant Staphylococcus aureus &#8211; MRSA strain.
Methods:
In this study an ethanol extract of Turnera ulmifolia L. and chlorpromazine were tested for their antimicrobial activity alone or in combination with aminoglycosides against an MRSA strain.
Results:
The synergism of the ethanol extract and aminoglycosides were verified using microdillution method. A synergistic effect of this extract on gentamicin and kanamycin was demonstrated. Similarly, a potentiating effect of chlorpromazine on kanamycin, gentamicin and neomycin, indicating the involvement of an efflux system in the resistance to these aminoglycosides.
Conclusion:
It is therefore suggested that extracts from Turnera ulmifolia could be used as a source of plant-derived natural products with resistance-modifying activity, constituting a new weapon against the problem of bacterial resistance to antibiotics demonstrated in MRSA strains.</description>
        <link>http://www.biomedcentral.com/1472-6882/9/13</link>
                <dc:creator>Henrique Coutinho</dc:creator>
                <dc:creator>Jose Costa</dc:creator>
                <dc:creator>Edeltrudes Lima</dc:creator>
                <dc:creator>Vivyanne Falcao-Silva</dc:creator>
                <dc:creator>Jose Siqueira-Junior</dc:creator>
                <dc:source>BMC Complementary and Alternative Medicine 2009, 9:13</dc:source>
        <dc:date>2009-05-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1472-6882-9-13</dc:identifier>
        <prism:publicationName>BMC Complementary and Alternative Medicine</prism:publicationName>
        <prism:issn>1472-6882</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2009-05-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
